Comparison of Efficacy of Romosozumab With Denosumab and Risedronate in Patients Newly Initiating Glucocorticoid Therapy
Authors' conclusion
Treatment with ROMO significantly increased lumbar spine BMD in glucocorticoid-treated patients, suggesting that ROMO is effective for GIOP.
Study context
- Population
- Patients with rheumatic diseases, no prior osteoporosis treatment, newly treated with prednisolone ≥15 mg/day
- Participants
- 11 / 14 / 14
- Comparison
- Romosozumab (ROMO) vs denosumab (DMAb) vs bisphosphonates (BP)
- ROMOn = 11
- DMAbn = 14
- BPn = 14
Primary result
As reported in the abstract
% change in lumbar spine BMD from baseline · 12 months
ROMO
8.6
median · IQR 3.1–12.4 · %
DMAb
3.3
median · IQR 1.5–6.2 · %
BP
−0.4
median · IQR −3.4–1.1 · %
Further findings
Bone turnover markers · 12 months
- Serum bone alkaline phosphatase slightly elevated with ROMO
- P1NP and osteocalcin decreased in all 3 groups; changes smaller with ROMO
- Serum bone resorption markers and a urine bone quality marker decreased in all groups
Original publication
Comparison of Efficacy of Romosozumab With Denosumab and Risedronate in Patients Newly Initiating Glucocorticoid Therapy. J Clin Endocrinol Metab. Published 18 November 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →